IP Library Granted Patent US 10,471,066
Granted Patent B2
US 10,471,066 · App. 15/817,470 · Granted Nov 12, 2019

Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists

Inventors: Per Sauerberg (Farum, DK); Pavel Pihera (Prague, CZ); Zdenek Polivka (Prague, CZ); Miroslav Havranek (Prague, CZ); Ingrid Pettersson (Frederiksberg, DK); John Patrick Mogensen (Herlev, DK)
Assignee: VTV THERAPEUTICS LLC
A61K31/5377A61K31/192A61K31/195A61K31/343A61K31/381A61K31/40A61K31/4025A61K31/415A61K31/4402A61K31/445A61K31/495A61K31/5375C07C59/70C07C217/48C07C323/16C07C323/32C07D211/46C07D213/30C07D213/36C07D231/12C07D265/30C07D295/096C07D295/112C07D307/79C07D307/81C07D333/16C07D333/20C07D333/54C07C2601/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,471,066
App. No.
15/817,470
Granted
Nov 12, 2019
Kind
B2
Abstract

Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein. The present compounds are activators of PPARδ and may be useful for treating conditions mediated by the same.

Claims (26)

1. A method of improving mitochondrial energy output in a subject, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein is a double bond, with either E or Z substitution;

X 1 is C 1-6 alkyl substituted with morpholino;

X 2 is phenylene;

X 3 is phenyl substituted with one or more halogens;

Ar is phenylene optionally substituted with methyl;

Y 1 is O;

Y 2 is CH 2 ;

Z is CH 2 ;

R 1 is hydrogen; and

R 2 is hydrogen.

2. The method of claim 1 , wherein X 1 is morpholin-4-ylmethyl.

3. The method of claim 1 , wherein the compound is (E)-[4-[3-(4-Chlorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methylphenyl]-propionic acid or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is (Z)-[4-[3-(4-Chlorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methylphenyl]-propionic acid or a pharmaceutically acceptable salt thereof.

5. A method of improving mitochondrial energy output in a subject, the method comprising administering to a subject in need thereof an effective amount of a compound of selected from the group consisting of:

(Z)-[2-Methyl-4-[3-(4-methylphenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-phenoxy]acetic acid;

(E)-[2-Methyl-4-[3-[4-[3-(pyrazol-1-yl)prop-1-ynyl]phenyl]-3-(4-trifluoromethylphenyl)-allyloxy]phenoxy]acetic acid;

(E)-[2-Methyl-4-[3-[4-[3-(morpholin-4-yl)propynyl]phenyl]-3-(4-trifluoromethylphenyl) allyloxy]-phenoxy]acetic acid;

(E)-[2-Methyl-4-[3-(4-methylphenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-phenoxy]acetic acid; and

(Z)-[2-Methyl-4-[3-[4-[3-(morpholin-4-yl)propynyl]phenyl]-3-(4-trifluoromethylphenyl) allyloxy]-phenoxy]acetic acid;

or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , wherein the compound is (Z)-[2-Methyl-4-[3-(4-methylphenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.

7. The method of claim 5 , wherein the compound is (E)-[2-Methyl-4-[3-[4-[3-(pyrazol-1-yl)prop-1-ynyl]phenyl]-3-(4-trifluoromethylphenyl)-allyloxy]phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.

8. The method of claim 5 , wherein the compound is (E)-[2-Methyl-4-[3-[4-[3-(morpholin-4-yl)propynyl]phenyl]-3-(4-trifluoromethylphenyl)allyloxy]-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.

9. The method of claim 5 , wherein the compound is (E)-[2-Methyl-4-[3-(4-methylphenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.

10. The method of claim 5 , wherein the compound is (Z)-[2-Methyl-4-[3-[4-[3-(morpholin-4-yl)propynyl]phenyl]-3-(4-trifluoromethylphenyl) allyloxy]-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2018
From: TRANSTECH PHARMA, INC.
To: HIGH POINT PHARMACEUTICALS, LLC
Reel/Frame 044536/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2018
From: NOVO NORDISK A/S
To: TRANSTECH PHARMA, INC.
Reel/Frame 044536/0159 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2018
From: TRANSTECH PHARMA, INC.
To: HIGH POINT PHARMACEUTICALS, LLC
Reel/Frame 044536/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2018
From: VTVX HOLDINGS II LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 044536/0318 →
CHANGE OF NAME Recorded Jan 4, 2018
From: HIGH POINT PHARMACEUTICALS, LLC
To: VTVX HOLDINGS II LLC
Reel/Frame 045002/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2018
From: SAUERBERG, PER; PIHERA, PAVEL; POLIVKA, ZDENEK; HAVRANEK, MIROSLAV; PETTERSSON, INGRID; MOGENSEN, JOHN PATRICK
To: TRANSTECH PHARMA, INC.
Reel/Frame 045003/0006 →
Priority Claims (2)
EP 05112758 · Dec 22, 2005 · regional
EP 06115631 · Jun 19, 2006 · regional
Continuity (6)
Continuation 15490205 · Apr 18, 2017
Continuation 14016442 · Sep 3, 2013
Division 13708163 · Dec 7, 2012
Continuation 13079460 · Apr 4, 2011
Continuation 12097564
Related Publication 20180071304A1 · Mar 15, 2018